Company previously received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland for the study
Execution of global patient enrollment continues to progress in pivotal study of Berubicin for the treatment of GBM, one of the most aggressive forms of brain cancer
https://finance.yahoo.com/news/cns-pharmaceuticals-receives-approval-competent-123500988.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.